About Us

Many patients would not be able to complete their childhood without the life-changing therapies in development at Andelyn Biosciences. By manufacturing gene therapies for clients worldwide, Andelyn is providing cures and hope for families looking for a healthy future.

Andelyn Biosciences was born out of Nationwide Children's Hospital and continues to have a close relationship with its world-class Abigail Wexner Research Institute.

The name “Andelyn” was chosen to pay tribute to two patients that participated in pivotal clinical trials at Nationwide Children's. Their combined names serve as a reminder that while  Andelyn is a biotech business, the patient is always first.

Our History

The road to the formation of Andelyn Biosciences started more than 15 years ago on the third floor of a research building at Nationwide Children’s Hospital. At that time, GMP facilities were unheard of at children’s hospitals and gene therapy research was a rarity.

Mission, Vision and Values

Andelyn Biosciences is driven by our fundamental purpose, highly reliable quality and unparalleled expertise. Our innovative manufacturing capabilities are paired with our clients’ life-changing research. Therapies for incurable diseases and rare disorders are the result.

The Inspiration in our Name

The corporate name “Andelyn Biosciences” represents a hybrid of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children’s Hospital.

Expanding Capabilities

Andelyn Biosciences’ ability to support Phase 3 trials will assist in furthering the field of gene therapy and supporting the evolution of pivotal studies. The company also has expanded its capabilities with the addition of a suspension cell production platform.